Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Swedbank AB

Key Points

• Swedbank AB has increased its holdings in Regeneron Pharmaceuticals by 2.0%, now owning 0.21% of the company, valued at approximately $119.9 million.
• Regeneron reported earnings of $12.89 per share for the latest quarter, significantly exceeding the consensus estimate of $8.43, and had a revenue of $3.68 billion.
• The stock is currently trading at $598.71 with a market cap of $63.46 billion, and has been rated as a "Moderate Buy" by analysts, with an average target price of $817.67.

Swedbank AB grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 228,297 shares of the biopharmaceutical company's stock after buying an additional 4,509 shares during the quarter. Swedbank AB owned approximately 0.21% of Regeneron Pharmaceuticals worth $119,856,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sovran Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $2,750,000. Gilman Hill Asset Management LLC increased its position in Regeneron Pharmaceuticals by 2.1% in the second quarter. Gilman Hill Asset Management LLC now owns 5,415 shares of the biopharmaceutical company's stock worth $2,843,000 after buying an additional 112 shares in the last quarter. DLK Investment Management LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $402,000. Balefire LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $201,000. Finally, Triumph Capital Management increased its position in Regeneron Pharmaceuticals by 42.4% in the second quarter. Triumph Capital Management now owns 843 shares of the biopharmaceutical company's stock worth $443,000 after buying an additional 251 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target for the company. in a report on Friday, August 1st. Finally, Truist Financial reduced their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Down 1.1%

NASDAQ:REGN traded down $6.72 on Friday, reaching $591.99. The stock had a trading volume of 2,177,965 shares, compared to its average volume of 914,839. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,154.56. The company has a 50-day moving average of $567.77 and a 200 day moving average of $575.13. The stock has a market cap of $62.74 billion, a P/E ratio of 14.92, a price-to-earnings-growth ratio of 1.98 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the company posted $11.56 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.